MARKET

CRMD

CRMD

Cormedix
NASDAQ
4.660
-0.180
-3.72%
After Hours: 4.710 +0.05 +1.07% 16:17 11/13 EST
OPEN
4.880
PREV CLOSE
4.840
HIGH
5.06
LOW
4.650
VOLUME
2.39M
TURNOVER
--
52 WEEK HIGH
13.02
52 WEEK LOW
4.650
MARKET CAP
370.36M
P/E (TTM)
2.187
1D
5D
1M
3M
1Y
5Y
1D
Deal Dispatch: Morgan Stanley Buys Vinyl Equity, Fox Completes Roku Acquisition, Children's Place Files for Chapter 11
Benzinga · 8h ago
Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike Deals
NASDAQ · 11h ago
CorMedix Price Target Cut to $13.00/Share From $15.00 by Oppenheimer
Dow Jones · 11h ago
Oppenheimer Reiterates Outperform on Cormedix, Lowers Price Target to $13
Benzinga · 11h ago
CorMedix Price Target Cut to $14.00/Share From $15.00 by RBC Capital
Dow Jones · 11h ago
CorMedix Is Maintained at Outperform by RBC Capital
Dow Jones · 11h ago
RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $14
Benzinga · 11h ago
CorMedix price target lowered to $13 from $15 at Oppenheimer
TipRanks · 13h ago
More
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.

Webull offers CorMedix Inc stock information, including NASDAQ: CRMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRMD stock methods without spending real money on the virtual paper trading platform.